The Impact of Gastroenterologist Dr. Ramnik Xavier
Ramnik Xavier is a key player and core institute member from the Broad Institute of MIT and Harvard and co-executive of the Broad's Infectious Disease and Microbiome Program.
He is also the Kurt Isselbacher Professor of Medicine at Harvard Medical School, executive of the Center for Computational and Integrative Biology, as well as a member of the Department of Molecular Biology at Massachusetts General Hospital (MGH); and co-chief of the Center for Microbiome Informatics and Therapeutics at MIT.
As a molecular biologist and clinical gastroenterologist, Xavier examines the particular sub-atomic components engaged with natural and versatile insusceptibility just as the hereditary variations related to Crohn's sickness, ulcerative colitis, and autoimmunity.
By determining the physiological elements of inflammatory bowel disease (IBD)- related polymorphisms, his work enlightens processes of essential mucosal homeostasis and aggravation.
Early Career and Education
Dr. Xavier is a Board Certified Gastroenterologist who received his MD at the University of Zimbabwe The Godfrey Huggins School of Medicine. He performed his residency at Massachusetts General Hospital and went on to a fellowship at Mass General in 1993.
Dr. Xavier finished his clinical preparation training in internal medicine, trailed by subspecialty preparing in gastroenterology and hepatology, at Massachusetts General Hospital. His lab is situated at the Center for Computational and Integrative Biology, of which he is a founder.
His detailed research and charismatic speaking abilities have provided him plenty of speaking arrangements. He is listed as the keynote speaker at the 2020 Microbiome Symposium which is being co-hosted by the Fred Hutch Microbiome Research Initiative and the University of Washington’s Center for Microbiome Sciences & Therapeutics (CMiST).
In 2016, Dr. Xavier was the keynote speaker at the 2016 AOA Groves Memorial Program Student Research Symposium and Dean’s Distinguished Lecture Series to give his “The Gut Circuit” talk. Students from around the country, medical professionals, and researchers packed the symposium to hear his presentation followed by student research presentations.
At the Center for Computational and Integrative Biology, Dr. Xavier runs Xavier Labs.
The essential research objective of the Xavier Laboratory at Massachusetts General Hospital and the Broad Institute is to find and comprehend the capacity of significant go-betweens and effectors associated with both the innate and versatile adaptive immune systems. Quite compelling are the cellular parts and regulatory systems that connect progressively inside temporal, spatial, and pathophysiological settings of natural resistance immunities.
A secondary focus area of the lab is to look at the pathway defects related to genetic variations in IBD and recognize novel small molecules that intrude on signal transduction pathways associated with disease risks.
For future research, the team at Xavier Labs has hopes to gather insights into the cell-cell interactions and regulatory networks of the immune system that define functional modules at the host cell-microbe interface within the intestinal mucosa. He continues to attract bright minds through his continued teaching at Harvard and MIT, and hopes to grow his research team in the future.
Comprehensive analysis of chromosomal mobile genetic elements in the gut microbiome reveals phylum-level niche-adaptive gene pools.
In this study, Xavier and his research team “curated a database of 5,219 putative MGEs encompassing seven MGE classes called ImmeDB.” MGEs in the gut microbiome can be beneficial or harmful to the body, depending on their type. Some mobile genetic elements carry genes that could confer an adaptive advantage to the gut environment. Antibiotic-resistant genes are also spread by some MGEs, and the analysis and classification of their differences will help doctors identify which ones are present in patients.
Transcriptional Atlas of Intestinal Immune Cells Reveals that Neuropeptide α-CGRP Modulates Group 2 Innate Lymphoid Cell Responses.
We already know that flagging irregularities in resistant reactions in the small digestive system can trigger chronic type 2 inflammatory issues, including connections with the interaction on multiple immune cell types. This study analyzed 58,067 immune cells taken from the small intestines of mice by single-cell RNA sequencing. Shifts in both cell-type composition and cell programs in response to the inflammation were discovered upon analysis.
The work done in this study, and research revealed a model “where α-CGRP-mediated neuronal signaling is critical for suppressing ILC2 expansion and maintaining homeostasis of type 2 immune machinery.” These findings are critical to future immune and inflammation studies surrounding CGRP, and have been cited in finding preventative measures for migraines caused by inflammation.
Calcitonin Gene-Related Peptide Negatively Regulates Alarmin-Driven Type 2 Innate Lymphoid Cell Responses.
Allergic inflammation is critically modulated by neuroimmune interactions, and type 2 innate lymphoid cells (ILC2s) have proven to be an essential cell type for mediation of these interactions. In this publication, Xavier and esteemed collaborators demonstrate that ILC2s express both neuropeptide calcitonin gene-related peptide (CGRP) and its receptor. There were marked changes indicated in ILC2 expression caused by CGRP interaction. There was a subset of distinct ILCs which scored very high for a CGRP-specific gene-signature which could suggest that CGRP regulates this response. In subjects who lacked the CGRP receptor, the study notes increased ILC2 proliferation and increased type 2 cytokine production and exaggerated responses with alarmins. The conclusion states that “endogenous CGRP is a critical negative regulator of ILC2 responses in vivo.”
Social Media Presence
In an announcement made on YouTube in February of 2019, Harvard celebrated Dr. Xavier and revealed a new program he’ll lead - The Microbiome: Emerging Opportunities for Biopharma. Dr. Stanley, Y. Shaw, who is the Associate Dean for Executive Education, Harvard Medical School stated in the video, “it is a new program that fills a critical need for a rigorous understanding of the latest developments in the microbiome field and the evidence supporting specific applications for biotech and pharmaceutical companies.” The course picked up steam on social media, with Harvard students hoping to become a part of this new program led by Dr. Xavier.
Awards and Accolades
- Named as a Core Member of the Broad Institute
- Kurt Isselbacher Associate Professor of Medicine at Harvard Medical School
- Co-Director of the Infectious Disease and Microbiome Program at the Broad Institute
Ramnik Joseph Xavier, MD, Ph.D., has made great strides in his research of immune systems and their connection to IBD. His patients receive top-notch care on a personal level, while he oversees his massive research team at Xavier Labs. H1 looks forward to seeing more connections of innate and versatile adaptive immune systems research from Xavier Lab in the future.